Eisai Co., Ltd. will present five abstracts across four tumor types at the Gastrointestinal Cancers Symposium (#GI21), which is being held virtually from January 15-17, 2021. Investigational data on the lenvatinib plus pembrolizumab combination that will be presented includes results from the Phase 2 LEAP-005 trial (NCT03797326) evaluating multiple cohorts of patients with previously treated solid tumors, including: gastric cancer (Abstract #230), biliary tract cancers (Abstract #321) and colorectal cancer (Abstract #94). Additional data to be presented include findings from a post-hoc analysis in patients with unresectable hepatocellular carcinoma (HCC) who progressed to Child-Pugh B liver function in the Phase 3 REFLECT trial (NCT01761266) evaluating lenvatinib (Abstract #298). Also, real-world effectiveness of lenvatinib monotherapy among unresectable HCC patients in the United States clinical practices will be presented (Abstract #273). In March 2018, Eisai and Merck (known as MSD outside the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib, both as monotherapy and in combination with Merck's anti-PD-1 therapy pembrolizumab. To date, 20 trials have been initiated under the LEAP (LEnvatinib And Pembrolizumab) clinical program, which is evaluating the combination across 13 different tumor types.